Ney Carter Borges: FAVOR III China Demonstrates a 37% Reduction in Myocardial Infarction with QFR Guidance
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn about a recent article by Han Zhang et al, published in JACC, adding:
”QFR-Guided PCI Improves 5-Year Outcomes: The FAVOR III China Trial
The FAVOR III China trial provides the longest follow-up to date evaluating an angiography-derived physiological strategy for guiding percutaneous coronary intervention (PCI).
In this multicenter, randomized study involving 3,825 patients with intermediate coronary stenoses, participants were assigned to PCI guided either by Quantitative Flow Ratio (QFR) or by conventional angiography alone.
After 5 years, QFR guidance significantly reduced the incidence of major adverse cardiovascular events (MACE) compared with angiography-guided PCI (17.5% vs 21.1%; HR 0.80; 95% CI 0.69–0.92; p=0.002).
This benefit was primarily driven by a 37% reduction in myocardial infarction (5.8% vs 9.0%; HR 0.63; p<0.0001) and a 22% reduction in ischemia-driven repeat revascularization (9.6% vs 12.0%; HR 0.78; p=0.02).
Overall mortality was similar between groups, confirming that the physiological strategy improves ischemic outcomes without affecting long-term survival.
An important finding is that QFR-guided PCI resulted in fewer procedures and fewer implanted stents, while achieving greater functional completeness of revascularization.
By identifying lesions that truly produced ischemia, QFR avoided unnecessary interventions without compromising safety.
Landmark analysis demonstrated that most of the clinical advantage occurred during the first two years after PCI.
From years 2 to 5, event rates became similar, suggesting that the principal benefit of physiological guidance is the optimization of the initial revascularization strategy rather than continuous divergence over time.
Clinical message: QFR offers a practical, wire-free physiological alternative to FFR, allowing more precise lesion selection while reducing procedural complexity.
These 5-year results reinforce QFR as an effective strategy to improve long-term clinical outcomes, decrease unnecessary stenting, and reduce myocardial infarction and repeat revascularization in patients undergoing PCI.”
Title: Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: 5-Year Follow-Up From the FAVOR III China Randomized Trial
Authors: Han Zhang, Changdong Guan, Zening Jin, Bo Yu, Guosheng Fu, Yujie Zhou, Jian’an Wang, Yundai Chen, Jun Pu, Lianglong Chen, Xinkai Qu, Junqing Yang, Xuebo Liu, Lijun Guo, Chengxing Shen, Yaojun Zhang, Qi Zhang, Hongwei Pan, Jian Liu, Yanyan Zhao, Yang Wang, Kefei Dou, Ajay J. Kirtane, Yongjian Wu, Weixian Yang, Shubin Qiao, Shengxian Tu, Gregg W. Stone, Lei Song

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop
-
Nov 17, 2026, 10:30Cheng-Hock Toh: Haematology Is Everywhere – But Is It Recognised?
-
Nov 17, 2026, 10:23Akshat Jain: The Importance of Knowing Your Sickle Cell Status
-
Nov 17, 2026, 10:12Caitlin Raymond: What Does Apheresis Really Cost?
-
Nov 17, 2026, 05:47Multidisciplinary Teams Kick Off SAHF MASAC ES 2026 with Pre-Symposium Workshops – South African Haemophilia Foundation
-
Nov 17, 2026, 05:41Boitumelo Malatji: South African Delegation Advances Advocacy Strategies at NNHF Southern Africa Workshop
-
Nov 17, 2026, 05:36Joining the PACTA Uganda Mental Health and Addiction Community Camp 2026 – Tackle Sickle Cell Africa
-
Nov 17, 2026, 05:30Nathan Connell: Women’s Hematology Summit 2027 to Address Hematologic Health Across the Lifespan
-
Nov 17, 2026, 05:25Mane Kurghinyan: Representing Armenia and HemAI Dynamics at the Falling Walls Lab Global Finale 2026